Gemini enters business combination deal with Disc Medicine
The proceeds will be utilised to advance the pipeline of Disc to clinical trials and provide runway into 2025.
Hematological Disorders
Latest in
Hematological Disorders
Pfizer signs agreement to acquire biopharma firm GBT for $5.4bn
GBT takeover complements and boosts Pfizer’s expertise in rare haematology.
Karyopharm receives US and Europe regulatory designations for eltanexor
Eltanexor is currently being analysed in an open-label Phase I/II trial in relapsed/refractory MDS patients.
Sobi enters licence agreement for ADC’s Zynlonta
Out of total payment of up to $435m, ADC Therapeutics will get an upfront payment of $55m from Sobi.
AstraZeneca signs agreement to acquire TeneoTwo
Following the acquisition, AstraZeneca plans to advance the development of TNB-486 for B-cell hematologic malignancies.
EC grants conditional approval for Janssen’s multiple myeloma cell therapy
The CMA is supported by the open-label, multi-centre Phase Ib/II CARTITUDE-1 clinical trial of cilta-cel to treat RRMM.
FDA approves Servier’s Tibsovo-azacitidine combo therapy for AML
The latest approval is based on findings from a Phase III AGILE clinical trial of Tibsovo plus azacytidine in AML…
FDA grants Orphan Drug Designation to Editas’ beta thalassemia therapy
The company intends to commence a Phase I/II trial of EDIT-301 in transfusion-dependent beta thalassemia patients this year.